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Abstract
Background: In patients at high risk for regional node metastasis from squamous cell carcinoma (SCC) of the skin
of the face, ear, or scalp, radiotherapy to the regional nodes is an alternative to parotid or neck surgery. Data on
the efficacy of elective nodal radiotherapy in this setting are scarce such that there is no publication specifically
addressing the subject. The purpose of our study is to fill this void in the skin cancer literature.
Methods: This is a single-institution study of outcomes following elective nodal radiotherapy in 71 consecutively
treated adults with SCC of the face, ears, or scalp. Primary site stage distribution per the American Joint Committee on
Cancer, 7th Edition, was as follows: T1, 15 %; T2, 34 %; T3, 1 %; and T4, 50 %. Other disease characteristics included the
following: clinical perineural invasion, 13 %; pathological perineural invasion, 78 %; recurrent disease, 32 %; and positive
or close margin, 67 %. The median radiation dose to the first- and second-echelon nodal area was 50 Gy. Acute and
late toxicity were graded per the Common Terminology Criteria for Adverse Events, version 4.0. Regional control was
assessed using the Kaplan-Meier product limit method.
Results: Median followup was 4.5 years for all patients. The actuarial regional control rate at 5 years was 96 %. There
were no (0 %) grade 3 or higher complications from elective nodal irradiation.
Conclusions: Elective nodal irradiation in patients with high-risk SCC of the face, ears and scalp is safe and effective.
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Background
Major risk factors found at the primary site that predis-
pose to nodal metastasis from squamous cell carcinoma
(SCC) of the skin include the following: tumor diameter >
2 cm, tumor thickness > 5 mm, poor differentiation, tumor
location within ear, age > 70 years, perineural invasion
(PNI), history of recurrence, and immunosuppression
[1, 2]. Elective neck surgery often including parotidect-
omy effectively prevents regional node recurrence, but
the morbidity of surgery in this setting is frequently
substantial [3, 4]. An alternative to elective neck sur-
gery is elective nodal irradiation (ENI) since many of
the cancers in which neck management is indicated
also present with indications for primary or adjuvant
radiation therapy (RT) to the primary site.
There is no study that focuses on ENI in SCC of the
skin of the face, head, or neck. A few publications
present subset analyses that address the ENI issue to
some degree, but to our knowledge, none of these stud-
ies describe overall risk factors in the ENI group, the
technical details of ENI, the actuarial risk of neck con-
trol following ENI, or toxicity related to ENI [5–7]. The
purpose of this study is to fill this void in the skin can-
cer literature.
Methods
Under the approval of the University of Florida Institu-
tional Review Board, we reviewed the medical records
of 71 patients with SCC of the skin of the face, ears, or
scalp treated at our institution with RT to the primary
site and regional lymphatics between 1985 and 2012.
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The year 1985 marks when our institution routinely
began using axial computed tomography (CT) or mag-
netic resonance imaging (MRI) to stage head and neck
cancer patients. This study is limited to patients who
received elective nodal radiotherapy, meaning there
was no clinical or radiographic evidence of nodal me-
tastasis and no history of surgery to the regional lym-
phatics. Throughout the 28-year period of this study it
was the policy in our department to add ENI in pa-
tients with recurrent tumors, poor differentiation, peri-
neural invasion, tumor size greater than 2 cm, positive
margin, or immunosuppression. This study is limited
to situations wherein a major change in treatment vol-
ume was made specifically to electively irradiate the
regional nodes. Not included in this study are cases
wherein inclusion of nodal tissue was only accom-
plished by enlarging the primary field a small amount.
ENI was delivered to the first-echelon nodal region in
all cases in this study. The distribution of first-echelon
nodal areas among our cohort was as follows: parotid,
75 %; facial, 37 %; retroauricular, 28 %; occipital, 10 %;
and cervical levels 1 and 2, 8 %.
Table 1 lists the relevant patient and tumor character-
istics. Clinical PNI was defined as a cranial nerve deficit
on physical examination and/or visible tumor in a
major cranial nerve branch on CT or MRI scan.
In addition to the information summarized in Table 1,
distribution of primary site location was as follows: ear
pinna (13 %), lateral cheek (11 %), temple (11 %), medial
cheek (10 %), nose (10 %), external auditory canal (9 %),
forehead (9 %), postauricular (7 %), posterior scalp (7 %),
anterior scalp (5 %), upper lip vermillion (4 %), upper lip
skin (3 %), and lower lip skin (1 %).
All patients in this study were clinically node-negative
based on physical examination and 85 % by axial CT or
MR scan. Primary site stage distribution per the American
Joint Committee on Cancer, 7th Edition [8], was as follows:
T1, 15 %; T2, 34 %; T3 1 %; and T4 50 %. Patients were
also staged according to a recently proposed, potentially
more relevant staging system employing risk factors (poor
differentiation, PNI, tumor diameter ≥2 cm, and invasion
of subcutaneous fat) [6]. Stage distribution per this pro-
posed system was as follows: T1 (0 risk factor), 6 %; T2A
(1 risk factor), 34 %; T2B (2-3 risk factors), 43 %; and T3
(4 risk factors), 17 %.
Based on the data from Mendenhall [1], O’Hara [2],
and Pahlajani [6], we estimate that the great majority
of patients in our study had at least a 10 % chance of
subclinical disease in the regional lymphatics. Table 2
summarizes the details of RT. In brief, the median ra-
diation dose to the primary site was 65 Gy (range, 38-
74 Gy), the median radiation dose to the first-echelon
nodal area was 50 Gy (range, 38-74 Gy), and the me-
dian radiation dose to the other nodal areas was 50 Gy
(range, 30-60 Gy). Three patients received concurrent
chemotherapy for advanced disease with carboplatin
and taxol (1 patient), carboplatin alone (1 patient) or
cisplatin alone (1 patient).
Table 1 Patient characteristics (N = 71)









Adjuvant RT (post-op) without visible tumor 53 (75)
Visible tumor present at time of RT 18 (25)
Recurrent after curative-intent surgery 23 (32)
Clinical perineural invasion 9 (13)
Cancer touches midline 17 (24)
Radiological and Pathological Risk Factors
>2 cm primary 36 (51)
> 5 mm thickness 24 (44)
>2 mm invasion 17 (31)
Subcutaneous fat invasion 10 (18)
Perineural invasion in pathology report 45 (76)
Lymph-vascular space invasion 8 (14)a
Bone invasion in pathology or imaging
report
8 (12)b




Positive margin 31 (56)c
Negative margin 18 (33)c
Close (< 5 mm) margin 6 (11)c
Differentiation
Well differentiated 15 (21)
Moderately differentiated 14 (20)
Poorly differentiated 25 (35)
Undifferentiated 2 (3)
Not Reported 15 (21)
Nodes negative by CT or MR scan 60 (85)
Characteristics Median value (range)
Age 69 years (33-95)
Days from previous treatment to recurrence 344 days (28-1078)
Notes: aThe percentage of patients was calculated with a total of 59 patients.
bThe percentage of patients as calculated with a total of 68 patients. cThe
percentage of patients was calculated with a total of 55 patients.
Abbreviations: RT, radiation therapy; CT, computed tomography; MR,
magnetic resonance
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Statistical analyses
The efficacy endpoint in this study is regional control,
which we define as freedom from tumor recurrence in
a lymph node. All statistical analyses were performed
using SAS and JMP software (SAS Institute, Cary, NC).
Regional control was assessed using the Kaplan-Meier
product limit method. The log-rank test statistic was
used to detect any statistically significant differences
between strata of selected explanatory variables.
The toxicity endpoint in this study is an effect that could
be related to elective nodal RT. We graded acute and late
toxicities with the most recent version of the National Can-
cer Institute Common Terminology Criteria for Adverse
Events, version 4.0 (CTCAE v4.0) [7]. In this retrospective
analysis we were not able to accurately report minor (grade
1 or 2) toxicities. For this reason our report is limited to
grade 3 to 5 toxicities.
Results
Follow-up
The median follow-up after the last day of RT was 4.5
years for all patients (range, 0.8-22.5 years), and 6.0 years
for living patients (range, 1.9-22.5 years).
Table 2 Radiation therapy (N = 71)
Treatment Characteristics Median value (range)
Radiation therapy duration (days) 44 days (16 to 55)
Primary site dose 65 Gy (38 to 74)
1st echelon node station dose 50 Gy (38 to 74)
Other node station dose 50 Gy (30 to 60)
Treatment Characteristic No. of patients (%)
Primary site radiation therapy modality
Orthovoltage (250-kV) 15 (21 %)
Electron 21 (30 %)
Cobalt-60 1 (1 %)
4- to 6-MV photon 20 (28 %)
Mixed photon-electron 14 (20 %)
First-echelon node radiation therapy modality
Orthovoltage (250 kV) 11 (15 %)
Electron 24 (34 %)
Cobalt-60 0 (0 %)
4- to 6-MV photon 24 (34 %)
Mixed photon-electron 12 (17 %)
First-echelon node radiation therapy technique
En-face Electron 24 (34 %)
En-face Mixed Electron-Photon 12 (17 %)
En-face Orthovoltage 11 (15 %)
6 MV Photon wedge pair 14 (20 %)
6 MV IMRT 7 (10 %)
Anterior 6MV Photon 3 (4 %)
Radiation therapy modality for other nodal
stations
Orthovoltage (250 kV) 0 (0)a
Electron 19 (32)a
Cobalt-60 4 (7)a
4- to 6-MV photon 34 (56)a
Mixed photon-electron 3 (5)a
Concurrent chemotherapy 3 (4)
Note: aThe percentage of patients as calculated with a total of 60 patients
Table 3 Characteristics of the 2 patients with isolated nodal
recurrence related to elective nodal irradiation
Characteristics Patient 1 Patient 2
Age (years) 64 75
Subsite Pinna Temple
First echelon treated Parotid Parotid





American Joint Committee on
Cancer, 7th ed., stage
T4 T1
Proposed 2013 Journal of American
Medical Association stage7
T2A T2A
Axial imaging performed Yes Yes
Immunosuppressed Yes No
Cancer touches midline No No
Clinical perineural invasion No No
Pathological perineural invasion Yes No
>2 cm primary No No
>5 mm thickness No No
>2 mm invasion No No
Invaded subcutaneous fat No No
Lymphovascular space invasion Yes No
Bone invasion on pathology or
imaging
No No
Cartilage invasion on pathology
or imaging
No No
Recurrent after curative-intent surgery Yes Yes
Days from first surgery to
radiotherapy start
244 323





Primary (Gy) 60 (once daily) 74 (twice daily)
1st Echelon (Gy) 46 (once daily) 74 (twice daily)
Rest (Gy) 50 (once daily) 46 (once daily)
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Regional control after elective nodal irradiation
The rate of isolated nodal recurrence in an area treated
with ENI was 2 of 71 (2.8 %). Table 3 summarizes the
details of these two cases.
In addition to 2 isolated nodal recurrences in areas of
ENI, 2 patients experienced nodal recurrence that we
do not attribute to ENI. One patient developed a nodal
recurrence in a contralateral level 1 node outside of the
RT target volume and would not have been removed
through an elective neck dissection; therefore, we do
not consider this event a failure of ENI compared to
the surgical alternative. An additional patient simultan-
eously recurred in the primary site and regional node,
which suggests that the nodal recurrence could be a
secondary event related to metastasis from the primary
site recurrence rather than failure of the ENI to sterilize
subclinical disease.
Fifteen patients recurred at the primary site (of these, 1
had a simultaneous nodal recurrence in the first-echelon
nodes and 14 never developed a nodal recurrence through-
out the follow-up period). The most reliable measure of
efficacy of ENI is the regional recurrence rate in pa-
tients who received ENI but remained continuously free
of recurrence at the primary site and the area which re-
ceived ENI: In our study, 2 of 56 patients recurred in
this area (3.6 %).
Figure 1 is an actuarial plot of regional control follow-
ing ENI. After rounding off to the nearest whole num-
ber, the actuarial 5-year rate of continuous freedrom
from a nodal recurrence (not including surgical salvage)
was 96 % for both the overall group of 71 patients and
for the 56 patients without a primary site recurrence.
Time to nodal recurrence after Elective Nodal Irradiation
All 4 nodal recurrences presented within 1 year of com-
pleting RT.
Regional control including surgical salvage of nodal
recurrence
In 3 of the 4 patients with a nodal recurrence, salvage
neck dissection was performed with curative intent (and
the patient who simultaneously recurred at the primary
site was also treated with resection of the primary site).
Salvage surgery was successful in 2 of the 3 patients who
underwent salvage attempt based on no evidence of
cancer at last follow-up (at least 1 year after salvage
Fig. 1 Kaplan-Meier curve of neck control with (n = 78) and without
(n = 56) local control
Table 4 First echelon nodal volumes treated and the techniques used.
Nodal Area (%) Most Common First Echelon
Nodal Area Treated (%)
Most Common Radiation
Technique Used (%)
2nd Most Common Radiation
Technique Used (%)
3rd Most Common Radiation
Technique Used (%)
Ear Pinna (13) Parotid (100) Photons (44) Electrons (22) Mixed (22)
Lateral Cheek (11) Parotid (100) Photons (38) Mixed (38) Electrons (13)
Medial Cheek (10) Parotid (100) Photons (29) Electrons (29) Mixed (29)
Temple (11) Parotid (100) Electrons (75) Mixed (13) Photons (13)
Nose (10) Facial (71) Orthovoltage (60) Photons (40) NA
External Auditory Canal (9) Parotid (100) Photons (67) Electrons (17) Mixed (17)
Forehead (9) Parotid (83) Electrons (100)
Post-auricular (7) Retro-auricular (100) Photons (40) Orthovoltage (40) Mixed (20)
Posterior Scalp (7) Occipital (80) Photons (50) Mixed (50) NA
Post-auricular (80) Mixed (50) Electrons (25) Photons (25)
Anterior Scalp (5) Parotid (75) Electrons (100) NA NA
Upper lip vermillion (4) Bilateral Cervical (66) Photons (100) NA NA
Upper lip skin (3) Facial (100) Photons (50) Orthovoltage (50)
Lower lip skin (1) Ipsilateral Cervical (100) Photons (100) NA NA
NA, not available
Mixed: includes the use of both electrons, orthovoltage and photons to achieve coverage of the indicated nodal area
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surgery). In the remaining patient, salvage surgery was
not attempted because of the extent of adenopathy and
underlying medical problems.
Toxicity of Elective Nodal Irradiation
There were no (0 %) grade 3 or higher toxicity events
that could be related to ENI.
Discussion
The primary value of this series is that it is the first
study to focus on the efficacy of ENI in a general popu-
lation of patients with SCC of the skin of the head and
neck, for whom this issue is most pertinent. We know of
only 3 other studies with data on this subject and none
include details about overall risk factors, ENI target
areas, ENI dose, or location of recurrence relative to
ENI [5, 9, 10].
The 1987 study by Mendenhall et al from our depart-
ment reported outcomes of patients treated with radio-
therapy for gross disease at the primary site [9]. Almost
half the patients had basal cell carcinoma and most were
not staged with cross-sectional imaging. The only data
relevant to our discussion is that, with ENI, 8 of 10 pa-
tients with recurrent SCC remained continuously free of
a nodal recurrence.
The 2005 study by Moore and colleagues reports
freedom from recurrence in 4 of 5 patients treated with
ENI, but it is unclear if the sole recurrence was local,
regional, or both [5]. In patients who present with par-
otid gland metastases, cervical ENI has been previously
shown to decrease neck failures from 50 % in observed
patients to 0 % in those treated with ENI [11]. The
more recent series from our department authored by
Balamucki and colleagues focuses on outcomes of pa-
tients with clinical or incidental PNI from basal or
squamous cell carcinoma of the skin [10]. With ENI,
the actuarial rate of regional control at 5 years was 96 %
in patients with clinical PNI and 100 % in patients with in-
cidental PNI.
Conclusions
The experience reported in this paper supports the
conclusion that, in patients with SCC of the skin of the
face, pinna, external auditory canal, or scalp, the rate of
nodal recurrence and toxicity is very low in areas that
receive at least 50 Gy of ENI. The implication of this
conclusion is that, in patients similar to the study
population, clinicians should consider ENI when the
risk of subclinical disease in the regional lymphatics is
considered to be high. This recommendation is sup-
ported by the 2015 guidelines from the National Com-
prehensive Cancer Center Network which include ENI
(50 Gy at 2 Gy per fraction) in patients with SCC of the
skin who are “at risk for subclinical disease” and have
not undergone elective neck dissection [12].
The nodal areas we treated in this study are listed in
Table 4. As this study was limited to patients who re-
ceived ENI, the data does not inform the question of in-
dications for elective treatment of the regional nodes,
how an approach using ENI compares to elective neck
dissection, or observation with treatment reserved for
salvage of nodal recurrence.
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